Respiratory News and Research

RSS

AstraZeneca, Rigel enter global license agreement for R256 inhaled JAK inhibitor to treat chronic asthma

AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.

19 Jun 2012

ALung completes pilot study of Hemolung RAS in COPD patients

ALung Technologies, Inc., a leading developer of innovative lung assist devices, presented an analysis of its recent clinical trial of the Hemolung Respiratory Assist System (RAS) in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD).

19 Jun 2012

Commensal bacteria essential to fight off viral infections

Healthy humans harbor an enormous and diverse group of bacteria and other bugs that live within their intestines. These microbial partners provide beneficial aid in multiple ways - from helping digest food to the development of a healthy immune system.

19 Jun 2012

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced new clinical data presented in an oral presentation for ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use at the 17th Congress of the European Hematology Association (EHA).

19 Jun 2012

Dehaier, Heyer enter into three-year strategic mutual cooperation agreement

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that the Company has entered into a three-year strategic mutual cooperation agreement with HEYER Medical AG, an internationally recognized, Germany-based company specializing in state-of-the-art inhalation and anesthesia equipment, oxygen concentrators, breathing therapy equipment and connecting equipment.

18 Jun 2012

Greater Than AIDS, Walgreens partner to mark National HIV Testing Day

Walgreens, the nation's largest pharmacy chain, and Greater Than AIDS, a coalition of public and private sector partners united in response to the domestic epidemic, are teaming with health departments and local AIDS organizations to provide FREE HIV testing at 47 Walgreens stores in 20 cities across the nation in June in support of National HIV Testing Day.

18 Jun 2012

Latest allergy research presented at EAACI Congress 2012

Ground-breaking research results about stress during pregnancy and changes in pollen potency across Europe will be presented - among other novel research - at the world's leading congress on allergy and immunology - the EAACI Congress 2012 - that will open tomorrow in Geneva, Switzerland.

16 Jun 2012

Civitas commences CVT-301 Phase 2a trial in Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today the initiation of a Phase 2a clinical trial in Parkinson's disease patients evaluating CVT-301, an inhaled formulation of levodopa (L-dopa), for the rapid relief from motor fluctuations.

16 Jun 2012

Risks for eczema in adults identified

Eczema is particularly common in women, and is associated with exposure to gas, dust and fumes, and other allergy-based diseases, the results of a Swedish study show.

15 Jun 2012

OSA independently linked with DPN in patients with type 2 diabetes mellitus

Obstructive sleep apnea (OSA) is independently associated with diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes mellitus (T2DM), according to a new study from researchers in the UK. The severity of DPN is also correlated with the degree of OSA and the severity of nocturnal hypoxemia.

15 Jun 2012

Positive top-line results from Teva’s GALA Phase III trial on RRMS

Teva Pharmaceutical Industries Ltd. today announced positive top-line results from the GALA (Glatiramer Acetate Low-Frequency Administration) Phase III clinical trial assessing the efficacy, safety and tolerability of 40 mg/1 ml glatiramer acetate injection (GA) administered subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis (RRMS) patients.

15 Jun 2012

High-efficiency oxygen inhaler from Dehaier

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that the Company has co-developed its "High-Efficiency Oxygen Inhaler" with Dr. Ding Jianzhang of Beijing Haidian Hospital, which is expected to begin selling in the third quarter of 2012 in mainland China.

15 Jun 2012

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced updated survival data from a pivotal Phase II clinical trial of single-agent brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplant (ASCT) showing that the median overall survival has not been reached after a 26.5 month median follow-up.

14 Jun 2012

ORMC offers bronchial thermoplasty for severe asthma

Doctors at Orlando Regional Medical Center (ORMC) are delivering heat directly to the source to treat patients with severe asthma - a respiratory disease that causes the airways in the lungs to narrow, making it difficult to breathe.

13 Jun 2012

FDA grants Fast Track designation to Edimer’s EDI200 for treatment of XLHED

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for EDI200, the company's novel, proprietary, recombinant protein.

13 Jun 2012

Vanderbilt first medical center in Nashville to offer bronchial thermoplasty for asthma

Hannah Andrews, 23, who has suffered from severe asthma since she was a child, is breathing easier now thanks to a new procedure offered at Vanderbilt known as bronchial thermoplasty.

12 Jun 2012

Sleep apnea may speed-up kidney decline

Patients with chronic kidney disease are commonly exposed to nocturnal hypoxia that may increase the rate of decline in kidney function, Canadian researchers report.

12 Jun 2012

OSA negatively impacts youths’ ability to regulate life skills

The number of children with obstructive sleep apnea (OSA) declines as they enter adolescence, but the teen years can be a devastating trial of behavior and learning problems for kids with persistent OSA, new research shows.

12 Jun 2012

Sucrose and menthol act independently to reduce coughing

Millions of Americans reach for their cough drops or syrup at the first sign of a cough. However, scientists are unsure if and how these popular remedies work. Now, new findings from the Monell Center suggest that sucrose and menthol, ingredients commonly regarded as flavorings in these preparations, each act independently to reduce coughing.

12 Jun 2012